Akshat Maneesh Patel

Akshat Maneesh Patel

Auto-generated profile, based on publicly available information

Akshat Maneesh Patel

UT Southwestern Medical Center Dallas Texas USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2022 in Practical Radiation Oncology
Verified
Journal Article
Closed access
APAkshat M. Patel
Akshat M. Patel
LWLindsey West
Lindsey West
PAPramukh S. Atluri
Pramukh S. Atluri
SYSofia F. Yi
Sofia F. Yi
SRSyed Rizvi
Syed Rizvi
KKKiran A. Kumar
Kiran A. Kumar

12 January 2022 in Neuro-Oncology Practice
Verified
Journal Article
Open access
PDF file
APAkshat M Patel
Akshat M Patel
OAOmer Ali
Omer Ali
RKRadhika Kainthla
Radhika Kainthla
SRSyed M Rizvi
Syed M Rizvi
Farrukh AwanFarrukh Awan
Farrukh Awan
SDSridevi Devaraj
Sridevi Devaraj
This study analyzes sociodemographic barriers for primary CNS lymphoma (PCNSL) treatment and outcomes at a public safety-net hospital versus a private tertiary academic institution. We hypothesized that these barriers would lead to access disparities and poorer outcomes in the safety-net population. We reviewed records of PCNSL patients from 2007–2020 (n = 95) at a public safety-net hospital (n = 33) and a private academic center (n = 62) staffed by the same university. Demographics, treatment patterns, and outcomes were analyzed. Patients at the safety-net hospital were significantly younger, more commonly Black or Hispanic, and had a higher prevalence of HIV/AIDS. They were significantly less likely to receive induction chemotherapy (67% vs 86%, P = .003) or consolidation autologous stem cell transplantation (0% vs. 47%, P = .001), but received more whole-brain radiation therapy (35% vs 16%, P = .001). Younger age and receiving any consolidation therapy were associated with improved progression-free (PFS, P = .001) and overall survival (OS, P = .001). Hospital location had no statistical impact on PFS (P = .725) or OS (P = .226) on an age-adjusted analysis. Our study shows significant differences in treatment patterns for PCNSL between a public safety-net hospital and an academic cancer center. A significant survival difference was not demonstrated, which is likely multifactorial, but likely was positively impacted by the shared multidisciplinary care delivery between the institutions. As personalized therapies for PCNSL are being developed, equitable access including clinical trials should be advocated for resource-limited settings.

11 May 2023
Verified
Book Chapter
Closed access
ZRZaid Abdel Rahman
Zaid Abdel Rahman
SASyed Ali Abutalib
Syed Ali Abutalib
AAAimaz Afrough
Aimaz Afrough
SASairah Ahmed
Sairah Ahmed
TATaha Al-Juhaishi
Taha Al-Juhaishi
JZJun Zou
Jun Zou


9 June 2023 in Hematological Oncology
Verified
Journal Article
Open access
MJM. Jackson
M. Jackson
APA. Patel
A. Patel
SAS. All
S. All
SBS. Brocklehurst
S. Brocklehurst
AAAimaz Afrough
Aimaz Afrough
SDSridevi Devaraj
Sridevi Devaraj

9 July 2021 in Research Square
Verified
Preprint
Open access
PDF file
APAkshat Maneesh Patel
Akshat Maneesh Patel
OAOmer Ali
Omer Ali
RKRadhika Kainthla
Radhika Kainthla
SRSyed M. Rizvi
Syed M. Rizvi
FAFarrukh T. Awan
Farrukh T. Awan
PGPraveen Ramakrishnan Geethakumari
Praveen Ramakrishnan Geethakumari
Purpose: Primary central nervous system lymphoma (PCNSL) is an aggressive disease with many tools for management that may be subject to resource barriers. This study compares the treatment patterns and survival outcomes among PCNSL patients treated at a safety-net hospital versus a tertiary academic institution.Methods:We retrospectively reviewed records of PCNSL patients from 2007-2020 (n = 95) at a public safety-net hospital (n = 33) and a private academic center (n = 62) staffed by the same university. Demographics, treatment patterns, and outcomes were analyzed.Results:Compared to the tertiary academic center, patients at the safety-net hospital were significantly younger, more commonly Black or Hispanic, and had a higher proportion of presenting patients with HIV. The safety-net hospital cohort was significantly less likely to receive induction chemotherapy (67% vs 86%, p = 0.003) than those at the academic center. Safety-net hospital patients were significantly less likely to receive autologous stem cell transplant (ASCT) consolidation (0% vs. 44%, p = 0.001) and had higher rates of consolidative WBRT (35% vs 15%, p = 0.001). Younger age and receiving consolidation were associated with improved progression-free survival (PFS, p = 0.001) and overall survival (OS, p = 0.001). Hospital location had no statistical effect on PFS (p = 0.725) or OS (p = 0.226) on age-adjusted analysis. Conclusions:Our study showed significant treatment differences between a public safety-net hospital and an academic cancer center reflecting access disparities. Despite variable treatment patterns, survival outcomes were not different. Further research is needed to determine optimal treatments for an orphan disease like PCNSL and it will be essential to advocate for equitable access in resource-limited settings.